Tetsuji Hashida

Dec 1, 2024 | jrheum.org | Masataka Kuwana |Naoko Wakasugi |Tetsuji Hashida |Satoshi Uno

To the Editor: In 2013, tacrolimus was approved in Japan for the treatment of interstitial lung disease (ILD) in patients with polymyositis (PM)/dermatomyositis (DM).1 Subsequently, Kuwana et al2 reported the 2-year interim prospective results of a postmarketing surveillance study, which found that tacrolimus-containing immunosuppressive regimens were well tolerated in patients with PM/DM-associated ILD.2 As the maximum 3-year surveillance period has been completed, we now report the safety...

Jun 1, 2024 | jrheum.org | Tsutomu Takeuchi |Naoko Wakasugi |Tetsuji Hashida |Satoshi Uno

Key Indexing Terms: immunosuppressive agent lupus nephritis postmarketing product surveillance Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease, predominantly affecting women of reproductive age.1,2 Asian populations are also disproportionately affected,1-3 with a reported prevalence of SLE in Japan of up to 38 per 100,000.3 SLE has a heterogeneous presentation, with clinical manifestations ranging from skin rashes to major organ involvement.1 Lupus nephritis...

Feb 9, 2024 | jrheum.org | Tsutomu Takeuchi |Naoko Wakasugi |Satoshi Uno |Tetsuji Hashida

Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis in Japan: 10-year analysis of the real-world TRUST study Tsutomu Takeuchi, Naoko Wakasugi, Tetsuji Hashida, Satoshi Uno, Hirofumi Makino The Journal of Rheumatology Feb 2024, jrheum.2023-0210; DOI: 10.3899/jrheum.2023-0210